Business context and reporting period
Repro-Med Systems, Inc. (the issuer named in this filing; the request identifies KORU Medical Systems) filed this unaudited Form 10-Q for the quarter ended November 30, 2014, and the nine months then ended. The company designs, manufactures, and markets medical devices, particularly for ambulatory infusion and emergency medical applications. Its principal products discussed include the FREEDOM60 infusion system, RMS High-Flo needle sets, and RES-Q-VAC suction products.
Financial results and liquidity
| Metric | Three months ended November 30 | Nine months ended November 30 |
|---|---|---|
| Net sales | 2014: $2.655 million; 2013: $2.180 million, up 21.8% | 2014: $7.797 million; 2013: $6.064 million, up 28.6% |
| Gross margin | 2014: 59.5%; 2013: 60.8% | 2014: 60.8%; 2013: 60.9% |
| Operating profit | 2014: $134,434; 2013: $240,613 | 2014: $694,597; 2013: $501,284 |
| Net income | 2014: $92,692; 2013: $161,954 | 2014: $453,742; 2013: $326,017 |
| Operating cash flow | Not presented for the quarter | 2014: $392,187; 2013: $599,102 |
Quarterly sales growth did not translate into higher profit: net income fell year over year, while nine-month net income increased. Quarterly EPS is shown as a dash in the filing; nine-month basic and diluted EPS were each reported as $0.01.
At November 30, 2014, cash and cash equivalents were $2.248 million and certificates of deposit were $259,470. Current assets were $6.032 million versus current liabilities of $1.192 million. Inventory rose to $1.571 million from $819,000 at February 28, 2014. The balance sheet lists no interest-bearing debt; management attributed lower interest expense to the retirement of long-term debt in 2013. The filing does not provide a separate debt maturity schedule.
Investing activities used $644,666, primarily for property and equipment ($552,060) and patents ($91,726). Financing provided $273,000 net from an equity sale, compared with $439,306 of debt repayments in the prior-year period. Cash increased by $20,521 over the nine months.
Material changes and management commentary
- Growth in domestic and international sales was led by FREEDOM60 and RMS High-Flo. Nine-month RES-Q-VAC sales declined amid softer domestic demand and a shift toward higher-growth infusion products, although quarterly RES-Q-VAC sales improved.
- Quarterly operating profit declined as selling, general and administrative expense rose to $1.257 million from $976,000 and research and development expense increased to $117,000 from $51,000. Management cited expanded sales and production staffing, higher compensation, trade-show spending, legal fees, and product-development investment.
- For the nine months, R&D expense rose to $407,000 from $132,000. Management cited development of new products and enhancements to existing lines. The company opened a second cleanroom in June 2014 and invested in equipment, facility upgrades, and intellectual property.
- Foreign-exchange losses increased to $33,198 for the nine months from $7,080, reflecting euro weakness; the quarter included a $23,483 currency loss versus a $3,910 gain a year earlier.
- Management expected revenues and available capital to meet or exceed liquidity needs for the next 12 months. It noted that accounts payable at period-end included large operating and capital invoices paid in December.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. Interim results are not necessarily indicative of full-year results.
Outlook, risks, contingencies, and unusual items
The filing gives no numerical revenue or earnings guidance. Management described investment in products and production capacity, and anticipated product introductions in the upcoming year. Outlook remains subject to market acceptance, reimbursement, regulatory approvals, competition, and access to capital.
Key disclosed risks include changes to Medicare or other reimbursement for infusion pumps and supplies; FDA and other government regulation; competitive products; market acceptance of FREEDOM60 and new products; dependence on successful R&D, patent protection, and key personnel; and limited liquidity or the need to raise capital. The company also noted that new drugs or treatment approaches could alter demand for its infusion system and needle sets.
The company is pursuing a declaratory judgment action against a competitor concerning patent claims related to its needle sets. The competitor asserted counterclaims that the company considers without merit; the case was in early-stage discovery. The company also reported legal spending to strengthen its patent position and support the litigation.
On August 8, 2014, the company sold 1 million common shares and warrants to purchase another 1 million shares at $0.45 per share for $288,000 gross proceeds and $273,000 net proceeds after fees. A director consulting agreement provides 420,000 shares valued at $0.20 per share over three years; the director received a previously approved $25,000 bonus in August to assist with taxes on the stock grant. The company leases an aircraft from an entity controlled by its president and was operating under a month-to-month arrangement after the original lease expired. No material subsequent events through January 14, 2015 were reported.
Investor verification priorities
- Whether sales growth and the expansion of FREEDOM60 and High-Flo continue, and how RES-Q-VAC demand develops.
- Whether higher R&D, staffing, trade-show, and patent-litigation costs translate into product growth and improved operating profitability.
- Inventory growth, year-end accounts payable and subsequent payments, and actual operating cash generation relative to management’s 12-month liquidity expectation.
- Medicare reimbursement continuity, regulatory status, competitive entry, and potential market effects from new drugs or treatment practices.
- Progress, costs, and possible outcomes of the patent litigation, and the effects of equity issuance, warrants, and director stock compensation on dilution.